Terumo Acquires OrganOx in $1.5 Billion Deal
Terumo, a leading medical device company, has entered into a definitive agreement to acquire OrganOx, a company specializing in organ preservation devices. The transaction is valued at approximately $1.5 billion and marks a significant step in the expansion of Terumo’s presence in the field of transplant technology.
As part of the deal, OrganOx will become a wholly owned subsidiary of Terumo. This follows an earlier investment by Terumo through its venture capital arm in March of this year, indicating a long-term strategic interest in the company's innovative approach to organ preservation.
By combining Terumo's extensive experience in medical device design with OrganOx's cutting-edge expertise in normothermic machine perfusion (NMP), the two companies aim to enhance the global availability of advanced organ preservation solutions. This collaboration is expected to bring about meaningful improvements in the quality and accessibility of transplant procedures worldwide.
A Commitment to Patient Care
Terumo CEO Hikaru Samejima emphasized the importance of addressing unmet needs in the field of organ transplantation. He stated, “Organ transplantation represents a last resort for patients with limited treatment options, and addressing the unmet needs in this area carries significant social value.”
He further highlighted that donated organs are a precious medical resource, and he praised OrganOx’s mission to deliver transplantable organs in optimal condition. “This aligns with our unwavering commitment to patients—Our Promise,” Samejima added.
Innovation in Organ Preservation
Founded in 2008 as a spin-off from the University of Oxford, OrganOx has developed NMP devices that significantly extend the preservation of organs. These devices circulate nutrient-rich solutions at near-body temperature, enabling real-time monitoring during transport. This technology allows for better assessment and maintenance of organ viability, which can improve transplant outcomes.
One of OrganOx’s most notable products is the metra liver NMP device, which received FDA approval in 2021. It has already been used in over 6,000 liver transplant procedures globally. The company is also developing a kidney NMP device, which is expected to be commercialized by 2030.
Expanding Access to Transplant Technology
OrganOx executive chairman Oern Stug described the company as a pioneer and leader in organ transplantation technology. He noted that the acquisition by Terumo will help expand the adoption of their platform, leveraging Terumo’s global infrastructure to benefit more patients around the world.
The deal is expected to address several critical challenges in the field of organ transplantation, including improving organ utilization rates, increasing the use of marginal donor organs, and enhancing post-transplant outcomes. By integrating these technologies, the combined entity aims to make a lasting impact on patient care and healthcare systems globally.
Addressing Key Challenges in Transplantation
The acquisition underscores the growing need for innovative solutions in the transplantation sector. With the demand for organs far outpacing supply, technologies like NMP offer a promising way to maximize the use of available organs and improve patient outcomes.
Terumo and OrganOx are well-positioned to lead this transformation, combining their respective strengths to create a more efficient and effective system for organ preservation and transplantation. As the industry continues to evolve, the integration of such technologies could play a crucial role in saving more lives and reducing the burden on healthcare systems worldwide.
0 comments:
Ikutan Komentar